Day One Biopharmaceutical Stock (NASDAQ: DAWN)

Day One Biopharmaceutical

DAY ONE BIOPHARMACEUTICALS I

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

Carvana

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATEC

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

CALC

CPSH

CVNA

DAWN

EFSH

ELAB

ENSC

LUXH

MDJH

RDDT

RELY

ROKU

ROOT

Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

Meta Photo by rafapress on Shutterstock

Price Target

Analyst Ratings

GKOS

GNRC

PEGA

QCOM

ZETA

Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday

movers image

BBLG

BLMZ

CERO

HOTH

INDV

IROQ

SLNA

TIVC

TWOU

VKTX

Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceuticals Inc

Dawn Protocol

DAWNRAYS PHARM HLDGS LTD by Dawnrays Pharmaceutical Holdings, Ltd.

Earnings

Press Releases

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

Management

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities

Biotech Investing: How PRVs Can Unlock Major Opportunities

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

PTCT

SWTX

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

CareDx

Chimerix

Cogent Biosciences

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Geron

GRAIL

Gyre Therapeutics

LENZ Therapeutics

MiMedx Group

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Myriad Genetics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Replimune Group

Spyre Therapeutics

Vir Biotechnology

Xencor

Zymeworks

Goldman Sachs

JP Morgan

Wedbush

HC Wainwright & Co.

Needham

Comments

Day One Biopharmaceutical

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga